By IT Correspondent
New Delhi, July 29:
A Bengaluru-based organisation has received approvals from the US Food and Drug Administration and the European Union for a device that can contain the spread of novel coronavirus.
The device named “Shycocan”- Scalene Hypercharge Corona Canon, is a small drum-like device, which can be fixed in offices, schools, malls, hotels, airports or any closed area for disinfecting surfaces. The device has been proven 99.9 per cent effective in neutralising the Spike-Protein or S-protein that are present in this virus, thus completely cutting off its transmission from one person to another, chairman of the Bengaluru-based Organisation- “De Scalene India”, Dr Rajah Vijay Kumar said and added that the approval for manufacturing the device came last week.
It does not cure an infected person but is highly efficient in containing the spread of deadly viruses in public areas, especially indoor spaces. “We have given a ‘humanitarian’ licence to a few companies in India and abroad to manufacture this,” Dr Kumar said. Europe, Mexico and the US-based companies have also approached for licences and we would be giving permission to manufacturers allowing the production of the device in large numbers as the demand will spike in coming days, Kumar said and added that three Indian companies have already entered into a licensing agreement.
”We have done studies on how it performs — it neutralises the Spike protein or the S protein that is basic to the novel-coronavirus’ structure. So if you deploy this device everywhere, possibly there will be global containment of the virus,” Dr Kumar added.
The device was first shipped to the United States in March for its due testing. And lab tests have shown that that one device can cover about 10000 cubic metres area.
The device floods a room or any indoor place with hundreds of electrons — even if an infected person comes into such a place, the electrons in the air would neutralise the potency of the virus in the aerosols caused by sneezing, cough, etc. It further neutralises the viruses that stick to surfaces. Thus drastically reducing the transmission via surface- or airborne transmission.
“We have got clearance from the US FDA agency under an enforcement directive for Covid-19 health emergencies. For the European Union too, we have got the certificate of conformity for which the Shycocan was put through nearly 26 tests – such as safety, efficacy, whether it has any harmful effects, whether it interferes with the working of other devices, or whether other devices deployed in any place would interfere with the performance of this device. It has been cleared through all this,” Dr Kumar said.
